Work

76P Real-world study of ESR1 mutation testing by liquid biopsy using digital PCR or NGS to guide elacestrant use in metastatic breast cancer patients

Year: 2025
Type: article
Abstract: The EMERALD trial (NCT03778931) showed improved PFS with elacestrant vs standard of care (SOC) endocrine therapy (ET) in patients with ER+/HER2− mBC and tumors harboring ESR1-mut after prior ET+CDK4/6i; HR=0.55; 95% CI, 0.39-0.77; P=0.0005 (Bidard 2022), leading to its approval by FDA, EMA, MHRA and other regulatory agencies. An Early Access Program (EAP) was initiated in Europe to enable patient access to elacestrant before reimbursement. The availability of elacestrant emphasizes the need for real-time mutation detection upon progression to guide treatments.
Source: ESMO Open
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W4410463539
FWCI: 0.737
Cites:
Cited by: 2
Related to: 10